A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer. For some patients, the removal of a lobe of lung may leave too little lung behind for easy breathing. For some of these patients, it may be possible to perform a smaller-scale surgery ("sub-lobar resection") and place a radioactive implant behind to prevent the cancer from growing back. This study will see how these patients do in terms of controlling their disease treated with a radioactive implant called Cesium-131.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 30, 2021 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- IsoRay Medical, Inc.
- Interventions being studied
- Radiation: Cesium-131 Brachytherapy Seed
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Patients must have suspicious lung nodule for clinical stage I/recurrent non-small cell Lung Cancer 2. Mass Tumor size \< 7 cm 3. Patient must have a CT scan of the chest with upper abdomen within 90 days prior to date of pre-registration. 4. Patient must have ECOG/Zubrod performance status 0,1, or 2.
1. Patient has already received high dose radiation to the area 2. Cancerous nodule is very close to the esophagus or spinal cord, thereby increasing the risk of radiation treatment 3. Pregnancy or unwillingness to practice a form of birth control (i.e. abstinence, oral contraceptives, etc.)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Weill Cornell Medical CollegeNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 30, 2021. Always confirm current availability with the study team.